KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Retained Earnings (2018 - 2025)

Castle Biosciences' Retained Earnings history spans 7 years, with the latest figure at -$224.3 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 12.07% year-over-year to -$224.3 million; the TTM value through Dec 2025 reached -$224.3 million, down 12.07%, while the annual FY2025 figure was -$224.3 million, 12.07% down from the prior year.
  • Retained Earnings for Q4 2025 was -$224.3 million at Castle Biosciences, down from $240000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $240000.0 in Q3 2025 and bottomed at -$226.0 million in Q1 2025.
  • The 5-year median for Retained Earnings is -$160.9 million (2022), against an average of -$142.5 million.
  • The largest annual shift saw Retained Earnings tumbled 162326.47% in 2024 before it soared 100.11% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$87.4 million in 2021, then plummeted by 84.19% to -$160.9 million in 2022, then skyrocketed by 100.08% to $136000.0 in 2023, then tumbled by 147251.47% to -$200.1 million in 2024, then dropped by 12.07% to -$224.3 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Retained Earnings are -$224.3 million (Q4 2025), $240000.0 (Q3 2025), and -$221.5 million (Q2 2025).